Clinical Trials Logo

Kidney Transplantation clinical trials

View clinical trials related to Kidney Transplantation.

Filter by:

NCT ID: NCT05200949 Completed - Clinical trials for Kidney Transplant Failure

SURGICAL EXPERIENCE ON RENAL TRANSPLANT COMPLICATIONS

IMPACT
Start date: January 1, 2013
Phase:
Study type: Observational

Kidney transplantation (KT) failure could be due to surgery dependent factors and particularly surgeon's experience. Objective: To assess the impact of the surgeon's experience on the post-operative outcomes to know if it safe for young surgeons to perform it.

NCT ID: NCT05153915 Completed - Clinical trials for Kidney Transplantation

A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Start date: December 30, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to observe the safety and efficacy of Modigraf in de novo pediatric allograft liver and kidney transplantation recipients. This study will also monitor dose changes and tacrolimus whole blood trough levels of Modigraf based immunosuppression regimen.

NCT ID: NCT05152628 Completed - Clinical trials for Kidney Transplantation

A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Start date: January 11, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the pharmacokinetics of tacrolimus following oral administration of Modigraf, after the first oral dose and at steady state in pediatric participants undergoing de novo allograft liver or kidney transplantation. This study will also observe the safety and efficacy of Modigraf in de novo pediatric allograft liver and kidney transplantation recipients.

NCT ID: NCT05142748 Completed - Clinical trials for Kidney Transplant Infection

Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital

Start date: September 1, 2019
Phase:
Study type: Observational

The investigators aimed to identify prognosis factors associated with in-hospital complications and assess the epidemiology, management, and outcomes of community-acquired pneumonia in a kidney transplant recipients' cohort. The investigators intend to identify each stay by a national database. Then they will be consulted by 2 clinicians to assert CAP clinical definition. After that radiographic evidence will be reviewed to validate CAP diagnoses. Then clinical data are collected in each center.

NCT ID: NCT05124444 Completed - Clinical trials for Kidney Transplantation

TOlerance MOlecular and Genome-wide Studies With Renal Allograft Recipient Material

TOMOGRAM
Start date: August 22, 2015
Phase: N/A
Study type: Interventional

TOMOGRAM is a European multicentric, prospective, experimental, controlled study that aims to increase our understanding of the causative mechanisms of operational tolerance in kidney transplantation through the achievement of several multimodal whole-genomic analysis in human biological samples.

NCT ID: NCT05115435 Completed - Clinical trials for Kidney Transplant Patients

The Effect of Neuro Linguistic Programming on COVID-19 Fear in Kidney Transplant

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The study was conducted experimentally to evaluate the effect of neurolinguistic programming on COVID-19 fear in kidney transplant patients.

NCT ID: NCT05109455 Completed - Clinical trials for Kidney Transplant Infection

Effects of a Food Supplement in the Prevention of Urinary Tract Infections in Kidney Transplant Patients.

MANOTRAS
Start date: April 16, 2019
Phase: Phase 4
Study type: Interventional

The incidence of Urinary tract infections (UTIs) is very high in kidney transplant patients. Most UTIs occur during the first six months (82% within the first three months) of kidney transplantation and are frequently recurrent. The component D-mannose of our authorized food supplement acts by inhibiting the adherence of E.coli to the urothelium. It also has a controlled release formula that ensures the presence in urine of D-mannose and the other components during 24 hours. This is the reason why this experimental study aims to demonstrate that the oral intake of this food supplement is effective in the prevention of UTIs in kidney transplant patients.

NCT ID: NCT05057936 Completed - Covid19 Clinical Trials

Antibody After COVID-19 Vaccination

Start date: June 1, 2021
Phase:
Study type: Observational

Chronic kidney disease (CKD) including patients on dialysis and kidney transplant recipients. represents the special subgroups of patients that required protection during the Severe Coronavirus Disease 2019 (COVID-19) pandemic .Since COVID-19 is associated with severe morbidity and mortality in these particular subgroup of patients, the main strategies is proper and rapid vaccination. CKD patients usually have a reduced immune responses, vaccination in these group of patients usually require higher dosage and more frequent dose since the vaccine response is short-lived and less response especially in dialysis patients5 .In patients with normal renal function,the immunity is durable but with modest declines at 6-8months. One study showed a linear decline in IgG in dialysis patients for up to 3months , but there are otherwise limited data. Previous reports of the vaccination in CKD patient involved mainly the mRNA vaccines. The recent reports of seroconversion rate dialysis patients receiving two doses of BNT 162b2 vaccine (Pfizer BioNtech) was lower than in control. In Thailand, the main vaccines available are Coronavac (Sinovac Life Science, Beijing, China) and ChadOx1 nCoV-19 (Oxford-Astra Zeneca) which was dispensed all over the country since April 2021. Data of the efficacy and safety of these vaccines in these patient groups is lacking. Therefore, the aim of this study is to measure the antibody and cellular responses in CKD patients including those with dialysis therapy and kidney transplantation and monitor the adverse events after the first and second doses of after vaccination. The incidence rate of Sars-COV2 infection post vaccination was also observed.

NCT ID: NCT05029310 Completed - Kidney Transplant Clinical Trials

Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients

TACPAT
Start date: September 1, 2021
Phase: Phase 4
Study type: Interventional

Patiromer lowers potassium effectively in patients with hyperkalemia and chronic kidney disease. Patients with a kidney transplant usually have reduced renal function and may also develop hyperkalemia. However, potential interactions between immunosuppressive medications and patiromer have not been evaluated. These interactions could involve change in AUC of immunosuppressive drugs, such as calcineurin inhibitors or mycophenolate, or increased risk of hypomagnesemia, since both tacrolimus and patiromer have this potential side effect. We wish to evaluate potential interactions to ensure safe use of this drug in the transplant population.

NCT ID: NCT04969263 Completed - Clinical trials for Kidney Transplant Recipients

COVID-19 Protection After Transplant Pilot Study

CPAT
Start date: August 10, 2021
Phase: Phase 2
Study type: Interventional

Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown. Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim of this study is to elicit an antibody response to vaccination against SARS-CoV-2 in kidney transplant recipients who have failed to respond to two doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) vaccine.